CO2019007879A2 - Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización - Google Patents
Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilizaciónInfo
- Publication number
- CO2019007879A2 CO2019007879A2 CONC2019/0007879A CO2019007879A CO2019007879A2 CO 2019007879 A2 CO2019007879 A2 CO 2019007879A2 CO 2019007879 A CO2019007879 A CO 2019007879A CO 2019007879 A2 CO2019007879 A2 CO 2019007879A2
- Authority
- CO
- Colombia
- Prior art keywords
- tebipenem pivoxil
- salt
- methods
- tebipenem
- pivoxil
- Prior art date
Links
- 229950007537 tebipenem pivoxil Drugs 0.000 title abstract 11
- SNUDIPVBUUXCDG-QHSBEEBCSA-N tebipenem pivoxil Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 SNUDIPVBUUXCDG-QHSBEEBCSA-N 0.000 title abstract 9
- -1 them Chemical compound 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical class CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 229950008913 edisilate Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000002688 maleic acid derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación está dirigida a nuevas sales cristalinas de tebipenem pivoxil, lo que incluye una forma de sal cristalina etanosulfónica de tebipenem pivoxil (Forma A), una forma de sal cristalina cetoglutárica de tebipenem pivoxil (Forma A), formas de sales de maleato de tebipenem pivoxil (Forma A y Forma B), una forma de sal de maleato de tebipenem pivoxil (Forma A), una forma de sal metanosulfónica de tebipenem pivoxil (Forma B), una forma de sal de hidrobromuro de tebipenem pivoxil (Forma B), y una forma de sal de edisilato de tebipenem pivoxil (Forma A). La divulgación además incluye una composición, la que comprende una sal cristalina de tebipenem pivoxil y un portador aceptado para su uso en la farmacéutica y también incluye un método para tratar una infección resistente a los antibióticos, el cual comprende la administración a un paciente que necesite dicho tratamiento de una cantidad terapéuticamente efectiva de una sal cristalina de tebipenem pivoxil.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455109P | 2017-02-06 | 2017-02-06 | |
| PCT/US2018/017067 WO2018145089A1 (en) | 2017-02-06 | 2018-02-06 | Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019007879A2 true CO2019007879A2 (es) | 2019-07-31 |
Family
ID=61244766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0007879A CO2019007879A2 (es) | 2017-02-06 | 2019-07-22 | Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10889587B2 (es) |
| EP (1) | EP3577119A1 (es) |
| JP (1) | JP7309607B2 (es) |
| KR (1) | KR102608037B1 (es) |
| CN (2) | CN110234651A (es) |
| AU (2) | AU2018215687B2 (es) |
| BR (1) | BR112019015487A2 (es) |
| CA (1) | CA3049690C (es) |
| CO (1) | CO2019007879A2 (es) |
| EA (1) | EA201991618A1 (es) |
| IL (1) | IL268092B2 (es) |
| MX (1) | MX2019009288A (es) |
| NZ (1) | NZ753781A (es) |
| PH (1) | PH12019501245A1 (es) |
| WO (1) | WO2018145089A1 (es) |
| ZA (2) | ZA201903310B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3049690C (en) | 2017-02-06 | 2023-03-21 | Spero Therapeutics, Inc. | Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use |
| CN110804057A (zh) * | 2019-11-11 | 2020-02-18 | 浙江海翔药业股份有限公司 | 替比培南酯氢溴酸盐晶型及其制备方法、药物组合物和制药用途 |
| AU2021378320A1 (en) | 2020-11-11 | 2023-06-22 | Spero Therapeutics, Inc. | High dosage tebipenem pivoxil tablet formulation |
| CN112812116A (zh) * | 2020-12-31 | 2021-05-18 | 山东华鲁制药有限公司 | 一种药用替比培南匹伏酯的制备方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| AU682510B2 (en) * | 1993-07-01 | 1997-10-09 | Pfizer Japan Inc. | 2-(1-(1,3-thiazolin-2-yl)azetidin-3-yl)thio-carbapenem derivatives |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| JP3317604B2 (ja) | 1994-12-28 | 2002-08-26 | 日本ワイスレダリー株式会社 | 結晶形態のカルバペネム化合物 |
| TW420681B (en) | 1995-12-08 | 2001-02-01 | Lederle Japan Ltd | Carbapenem-3-carboxylic acid ester derivatives |
| JP3317649B2 (ja) | 1997-01-13 | 2002-08-26 | 日本ワイスレダリー株式会社 | 結晶形態のカルバペネム化合物 |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| KR100950699B1 (ko) | 2008-03-28 | 2010-03-31 | 국제약품공업주식회사 | 2-아릴메틸아제티딘-카바페넴-3-카복실산 에스테르유도체의 산부가염, 이의 제조방법 및 이를 포함하는 약학조성물 |
| KR100930586B1 (ko) * | 2007-11-23 | 2009-12-09 | 한국화학연구원 | 2-아릴메틸아제티딘-카바페넴-3-카복실산 에스테르 유도체,이의 제조방법 및 이를 포함하는 약학 조성물 |
| US20110118229A1 (en) | 2007-11-23 | 2011-05-19 | Kukje Pharm. Ind. Co., Ltd. | 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its salt, process for the preparation thereof and pharmaceutical composition comprising the same |
| CN102558181B (zh) | 2010-12-15 | 2015-04-22 | 石药集团中奇制药技术（石家庄）有限公司 | 一种碳青霉烯抗生素的制备方法 |
| CN102731507B (zh) | 2011-04-13 | 2015-04-01 | 石药集团中奇制药技术（石家庄）有限公司 | 泰比培南晶型、其制备方法及其在制备药物中的应用 |
| CN102276611B (zh) | 2011-05-18 | 2013-01-09 | 深圳万乐药业有限公司 | 一种替比培南酯的重结晶精制方法 |
| CN103664948B (zh) | 2012-09-05 | 2015-12-16 | 凌沛学 | 一种替比培南酯的中间体的结晶及其制备方法 |
| CN103664949A (zh) | 2012-09-12 | 2014-03-26 | 高瑞耀业(北京)科技有限公司 | 替比培南匹伏酯结晶及其制备方法 |
| CN106543186A (zh) | 2016-11-07 | 2017-03-29 | 山东大学 | 一种替比培南匹伏酯的单晶a及其制备方法 |
| CA3045566C (en) | 2016-12-15 | 2024-04-09 | Spero Therapeutics, Inc. | Tebipenem pivoxil immediate and modified release oral dosage forms |
| CA3049690C (en) | 2017-02-06 | 2023-03-21 | Spero Therapeutics, Inc. | Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use |
| CN108640920B (zh) | 2018-04-03 | 2020-03-27 | 科兴生物制药股份有限公司 | 一种替比培南酯的制备方法 |
| CN109096283A (zh) | 2018-09-03 | 2018-12-28 | 成都倍特药业有限公司 | 一种高纯度替比培南酯晶体的制备方法 |
| CN109651372A (zh) | 2018-12-27 | 2019-04-19 | 开封制药(集团)有限公司 | 一种替比培南酸的制备方法 |
-
2018
- 2018-02-06 CA CA3049690A patent/CA3049690C/en active Active
- 2018-02-06 MX MX2019009288A patent/MX2019009288A/es unknown
- 2018-02-06 US US16/483,989 patent/US10889587B2/en active Active
- 2018-02-06 CN CN201880009327.1A patent/CN110234651A/zh active Pending
- 2018-02-06 NZ NZ753781A patent/NZ753781A/en unknown
- 2018-02-06 KR KR1020197023950A patent/KR102608037B1/ko active IP Right Grant
- 2018-02-06 BR BR112019015487-6A patent/BR112019015487A2/pt active Search and Examination
- 2018-02-06 JP JP2019542373A patent/JP7309607B2/ja active Active
- 2018-02-06 EP EP18706094.2A patent/EP3577119A1/en active Pending
- 2018-02-06 WO PCT/US2018/017067 patent/WO2018145089A1/en active Application Filing
- 2018-02-06 EA EA201991618A patent/EA201991618A1/ru unknown
- 2018-02-06 CN CN202311492390.4A patent/CN117551102A/zh active Pending
- 2018-02-06 AU AU2018215687A patent/AU2018215687B2/en active Active
-
2019
- 2019-05-24 ZA ZA2019/03310A patent/ZA201903310B/en unknown
- 2019-06-04 PH PH12019501245A patent/PH12019501245A1/en unknown
- 2019-07-16 IL IL268092A patent/IL268092B2/en unknown
- 2019-07-22 CO CONC2019/0007879A patent/CO2019007879A2/es unknown
-
2020
- 2020-12-03 AU AU2020281120A patent/AU2020281120A1/en not_active Abandoned
- 2020-12-29 US US17/136,759 patent/US11718621B2/en active Active
-
2021
- 2021-05-24 ZA ZA2021/03498A patent/ZA202103498B/en unknown
-
2023
- 2023-06-09 US US18/332,566 patent/US20230331728A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019009288A (es) | 2019-09-10 |
| CA3049690A1 (en) | 2018-08-09 |
| BR112019015487A2 (pt) | 2020-03-31 |
| IL268092A (en) | 2019-09-26 |
| AU2020281120A1 (en) | 2021-01-07 |
| NZ753781A (en) | 2022-10-28 |
| KR20190115000A (ko) | 2019-10-10 |
| JP7309607B2 (ja) | 2023-07-18 |
| AU2018215687B2 (en) | 2020-09-03 |
| US20200055857A1 (en) | 2020-02-20 |
| ZA201903310B (en) | 2021-09-29 |
| WO2018145089A1 (en) | 2018-08-09 |
| PH12019501245A1 (en) | 2020-03-02 |
| IL268092B2 (en) | 2023-02-01 |
| CA3049690C (en) | 2023-03-21 |
| CN117551102A (zh) | 2024-02-13 |
| US10889587B2 (en) | 2021-01-12 |
| US20230331728A1 (en) | 2023-10-19 |
| IL268092B (en) | 2022-10-01 |
| JP2020506196A (ja) | 2020-02-27 |
| EA201991618A1 (ru) | 2020-01-30 |
| AU2018215687A1 (en) | 2019-06-13 |
| EP3577119A1 (en) | 2019-12-11 |
| CN110234651A (zh) | 2019-09-13 |
| ZA202103498B (en) | 2023-01-25 |
| US11718621B2 (en) | 2023-08-08 |
| US20210122753A1 (en) | 2021-04-29 |
| KR102608037B1 (ko) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019007879A2 (es) | Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| NI201600166A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| NI201900119A (es) | Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue | |
| CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2018010951A2 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| BR112019002151A2 (pt) | usos de compostos de fórmula (i) e usos de uma composição | |
| CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
| CL2020001429A1 (es) | Tratamiento del vsr con producto combinado. | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| BR112018002681A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv? |